作者: Marwan Fakih
DOI: 10.2147/OTT.S3026
关键词:
摘要: Colorectal cancer continues to be an important public health concern, despite improvements in screening and better systemic chemotherapy. The integration of targeted therapies the treatment colon has resulted significant efficacy outcomes. Angiogenesis is for tumor growth metastasis target new biological agents. Bevacizumab a humanized recombinant antibody that prevents vascular endothelial factor (VEGF) receptor binding, inhibits angiogenesis growth. addition bevacizumab fluoropyrimidine-based chemotherapy, with or without irinotecan oxaliplatin, both first- second-line metastatic colorectal cancer, significantly increased median progression-free survival overall select randomized phase III studies. Ongoing studies are evaluating role adjuvant cancer. Common toxicities associated include hypertension, bleeding episodes, thrombotic events. This review will focus on paradigm management its side effects.